Fig 2: MEK inhibitor (trametinib) suppresses CD155 and CD112 surface expression of most AML cell lines (MOLM-13, MV-4-11, THP-1, KG-1) examined. Histograms of CD155 and CD112 expression in AML cell lines treated with trametinib (10 and 100 nM: yellow and green, respectively)/DMSO (red) for 48 h. AML, acute myeloid leukemia; MFI, mean fluorescence intensity.

Fig 3: FLT3 inhibitor (quizartinib and gilteritinib) treatment does not suppress CD155 and CD112 surface expression in acute myeloid leukemia cell lines without FLT3 mutations. Histograms of CD155 and CD112 expression in THP-1, K562 and NB-4 cells treated with quizartinib or gilteritinib (1 and 10 nM: yellow and green, respectively)/DMSO (red) for 48 h. FLT3, FMS-like tyrosine kinase 3; MFI, mean fluorescence intensity.

Fig 4: CD155 and CD112 mRNA expression is downregulated by FLT3 inhibitors in acute myeloid leukemia cells with FLT3 mutations. CD155 and CD112 mRNA expression levels in MOLM-13 and MV-4-11 cells exposed to FLT3 inhibitors (quizartinib or gilteritinib). Experiments were performed in triplicate. Data were statistically analyzed using the one-tailed unpaired t-test. *P<0.05. 18S rRNA, 18S ribosomal RNA; FLT3, FMS-like tyrosine kinase 3; NS, no significant difference.

Fig 5: FLT3 inhibitor (quizartinib and gilteritinib) treatment suppresses CD155 and CD112 surface expression in acute myeloid leukemia cell lines with FLT3 mutations. Histograms of CD155 and CD112 expression in MOLM-13 and MV-4-11 cells treated with quizartinib or gilteritinib (1 and 10 nM: yellow and green, respectively)/DMSO (red) for 48 h. FLT3, FMS-like tyrosine kinase 3; MFI, mean fluorescence intensity.